AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

AbbVie reported topline results from the Phase 3 CERVINO trial of etentamig in patients with relapsed or refractory multiple myeloma. The company said the investigational asset produced a 74% objective response rate and significantly improved progression-free survival against investigator’s choice of standard available therapies. The reported progression-free-survival hazard ratio was 0.40, corresponding to a 60% reduction in the risk of disease progression or death versus the control arm.

The trial addresses a heavily treated multiple-myeloma population, where treatment response and the durability of disease control are central measures of clinical value. The announcement provided the topline efficacy figures, but did not include the full follow-up, overall-survival data, safety tables or detailed subgroup results. Those omissions leave the size and persistence of the benefit beyond the headline measures unresolved.

For AbbVie, etentamig would add to a portfolio whose reported revenue was $61.2B in fiscal 2025, up 8.6% year over year. The mechanism linking the trial to the company is therefore pipeline optionality: a successful development and approval path could create another oncology revenue stream, while the current figures show only clinical-trial performance rather than booked sales. The company reported $2.36 in diluted EPS and a 6.9% net margin for the same fiscal period.

The evidence is positive but remains preliminary in the sense that AbbVie released topline results rather than a complete clinical dataset. The comparator was investigator’s choice, so the specific therapies used in the control arm and their distribution matter when assessing how broadly the result translates across clinical practice. Regulatory authorities will also assess the full benefit-risk profile, including safety and follow-up data that were not detailed in the announcement.

Next, the key disclosures are the complete CERVINO dataset, the timing and content of any regulatory submission, and subsequent agency decisions. Investors will also need to see whether the 74% response rate is sustained with longer follow-up and whether the progression-free-survival advantage remains consistent across relevant patient groups. AbbVie’s future reports should clarify whether etentamig has begun contributing revenue or remains a development-stage asset.